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1. Introduction 
Oral drug delivery is the majority favored route of drug 
delivery. Suspensions are uniform dispersion of solid drug particles in a 
vehicle in which the drug has minimum solubility. Liquid dosage form is 
more favored than solid because of the flexible dosage administration and 
easy to swallow. In controlled release (CR) form is more patient 
compliant with less significant side effects and improved bio-availability. 
Suspension is a dispersion system consists of; particulate matter 
(dispersed phase) and continuous medium (dispersion medium) and in 
which the internal phase is dispersed uniformly consideration the 
external phase. Suspensions are the biphasic liquid dosage forms of 
medicament in which the finely divided solid particles ranging from 0.5 to 
5.0 micron dispersed in a liquid or semisolid vehicle. Suspensions are 
generally in use as orally or by parenteral’s route.  They are also used for 
external applications. The particle sizes of disperse phase play an 
important role in suspensions. To avoid gritty feeling to the skin and to 
cover a greater area of the applications, the suspension containing the 
smaller size of particles this is intended for external use. Moreover the 
smaller particle can penetrate easily into the skin and gives the faster 
dissolution. For the parenteral’s suspension particles having the as much 
size that easily pass through needle. The particle size of dispersed phase 
should not above than 10 micron. Suspensions are commercial dry 
mixtures that require the addition of water at the time of dispensing so, 
there is requires mixing prior to administration. Formulated suspension 
is first choice when drug stability is a major concern [1,2]. 
 
2. Formulated ingredients for reconstitutable SR 
suspension 
 Selecting ingredients are based on both suitability for 
reconstitution and the physical type of power mixture product. There are 
ingredients separated into two categories of frequent and infrequent use. 
Majority drug formulated as Reconstitutable oral suspensions mainly are 
antibiotics. Frequent used ingredients are suspending agents, wetting 
agents, sweetener, preservatives, flavors, colors and buffers etc. 
Infrequent used ingredients are anti-caking agents, flocculating agents, 
solid diluents, antifoaming agents, granule binders, granule disintegrants, 
antioxidants and lubricants. 
Table 1: Formulated ingredients for reconstitutable SR suspension 
No Ingredients Examples 
1 Suspending agent Acacia, CMC sodium, Iota-carrageenam, MCC with CMC sodium, Povidone, Propylene glycol alginate, Silicone dioxide, Colloidal, 
SSG, Tragacanth and Xanthan gum 
2 Wetting agent Polysorbate-80, Acacia, Tragacanth, alginate, Gaur gum, Pectin, Gelatin, Wool fat, Egg yolk, Bentonite, Veegum and Methyl 
cellulose 
3 Sweetener Sucrose, Mannitol, Dextrose, Aspartame and Sodium saccharin 
4 Preservative Propylene-glycol, Benzoalkonium chloride, Benzoic acid, Cetrimide, Cholorobutenol, Disodium EDTA etc. 
5 Antioxidants Ascorbic acid, Tocopherols,  Butylated  hydroxy anisole (BHA), Butylated hydroxytoluene (BHT),  Sodium bi sulfite, Sodium 
sulfateacetone , thio glycerol, cytosine, acetylcysteine 
6 Flavor Raspberry, Pineapple and Bubble gum 
7 Buffer Citric acid is most preferable used to stabilize pH of suspension between 3.5-5.0%, acetates 1-2%, citrates 1-5%, and 
phosphates 0.8-2% etc. 
8 Color (i)White-Titanium dioxide, Blue-brilliant blue, indigo carmine, indigo, (ii) Red-amaranth, carmine, (iii) Yellow- taratartarazine, 
sunset yellow, carrots, annatto seeds, madder plant, (iv) Green-chlorophyll, (v) Brown- caramel etc. 
Abstract 
At the present time reconstitutable suspensions are obtainable in a market. Oral 
liquor suspensions are majorly designed for the patients with difficulty in swallowing. 
Reconstitutable suspensions necessitate water to prior for mixing. Sustained release (SR) 
suspensions aimed at controlling the rate of release by maintaining desire drug levels in the 
blood for long duration of time. An oral suspension could be the most excellent fitting dosage 
form intended for geriatric and pediatric patients. They comprise improvement of the rate and 
extent of drug absorption, higher patient compliance, reduction of side effects and taste 
masking of bitter drug. Reconstitutable SR suspensions are prepared by numerous novel 
approaches to design and development of variety of drugs. They are prepared by using a variety 
of polymer like Cellulose acetate, EC (Ethyl Cellulose), HPMC phthalate, Eudragit, Xanthan gum 
etc. for enteric coating purpose, which are give controlled drug delivery from the granules. SR 
suspension developed into the research characterized by Scanning electron microscopy (SEM), 
particle size analysis, drug entrapment efficiency, and In-vitro Drug Release. SR suspension will 
be benefited to avoid fluctuations in blood drug plasma concentration and gives its action for an 
entire period of time. 
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3. Qualities of ideal Suspension [3,5] 
A well formulated suspension should have the following 
properties; 
 The dispersed particle should not settle readily and the settle should 
Re-dispersed immediately on shaking. The easy Re-dispersion of 
sediment particles in a suspension is important for the uniformity of 
dose.  
 The particles should not form cake on setting. 
 The viscosity should be such that the preparation can be easily 
poured. A highly viscous suspension would make pouring difficult.         
 It should be chemically and physically stable.  
 It should be palatable (orally). 
 It should be free from gritting particles (external use).  
 It should be chemically inert. 
 The dispersed particles are small and uniform. 
 It should be free from large particles which spoil its appearance, give a 
gritty taste to oral preparations and also cause irritation to sensitive 
tissues when applied externally. 
 
4. Challenge in formulation of oral suspension 
 Physical stability: The properties of a solid-liquid dispersion system 
alter the physical stability as well as the absorption rates of the 
formulation. 
 An acceptable organoleptic property like taste is hard to achieve and 
thus reduce the patience compliance.  
 
5. Method of Preparation [4,5,6] 
a) Ion exchange resin (IER) technique 
b) Saturated drug suspension as a suspending medium. 
c) Using non aqueous vehicle. 
d) Using reconstitution technique 
e) By using protective coating method 
f) Emulsion–solvent evaporation (o/w, w/o, w/o/w) methods 
g) Polymerization by phase separation methods 
h) Microencapsulation Methods  
Two types of microencapsulation system include physical and 
chemical methods. 
 Physical method 
o Air suspension coating 
o Rotary disk atomization 
o Fluidized bed coating 
o Stationary nozzle co-extrusion 
o Submerged nozzle co-extrusion 
o Centrifugal extrusion 
o Multi-orifice centrifugal process 
o Spray drying and congealing techniques 
o Pan coating  
 Chemical method 
o Co-acervation phase separation 
o Solvent evaporation techniques 
o Polymerization 
o Liposome technology 
o Nano-encapsulation 
o Solvent extrusion 
o Simplex and complex co-acervation 
 
6. Novel Pharmaceutical Reconstitutable suspension 
Jaber SH et al. formulate the Azithromycin suspension as an 
oral dosage form was carried out to prepare an acceptable suspension 
either as dry physical mixture or granules to be reconstituted, through 
studying the effect of various type and concentration of suspending agent 
[xanthan gum, Hydroxy propyl methyl cellulose (HPMC), either alone or 
combination] on the release profile of drug [7]. 
Sabri AS et al. prepare a stable suspension for rifampicin 
through preparation of different formulas of rifampicin aqueous 
suspension either as ready to use or as granular powder to be 
reconstituted. The chosen formulas was evaluated and compared with 
marketable brand to rifampicin as a reference through measuring their 
dissolution rates and other physical properties of result indicate that the 
selected formula have better dissolution rate compared with the 
reference suspension and the rheogram showed that the selected formula 
was less viscous than the reference one. Also, it was establish that the 
granuler rifampicin was more stable than the ready to use suspension, 
because the expiration date of granular rifampicin was 2.6 years, while 
the expiration date of ready to use suspension was 1.8 years [8]. 
Akre HS et al. prepare dry suspension of taste masked 
antibiotic drug intended for pediatric use. This is marketable dry 
mixtures that need addition of water at the time of dispensing. People 
require effective drugs that contain a nice taste so, can be administered 
easily. So, need to mask the unpalatable taste of a drug in order to 
improve the product quality. The solvent evaporation process is used for 
microencapsulation. Edragit L100 is used as taste masking agent. FT-IR 
study shows that there is no significant interaction occurring between 
drug and excipient [9].  
Aejaz A et al. prepare ready use suspension of ampicillin 
trihydrate used as antibacterial agent. It has poor stability in presence of 
water having shorter shelf life of about a week upon reconstitution. 
Therefore, it is try to formulate in to ready use oral suspension with 
improved stability and shelf life. In the initial approach, water was used 
as suspending medium and pH of formulation was selected in the range of 
5 to 6.5. Particle size determination revealed that majority of particle was 
in the size range of 15-75 mm [10].  
Jain DK et al. prepare reconstitutable oral suspension of 
ambroxol HCl and azithromycin. Reconstitutable oral suspension show 
adequate chemical stability of the drug during shelf life, avoids the 
physical stability problems. These are dry mixtures that require the 
addition of water at the time of dosing. The reconstitutable oral 
suspension of azithromycin and ambroxol HCl were found to be stable 
over its intended shelf life of 15 days after reconstitution. Formulation 
with xanthan gum (1.5% and 0.75%) showed excellent sedimentation 
volume and degree of flocculation nearing 1. and this was due to presence 
of anti caking agents or the granules disintegrate added to the 
formulations. Also formulation with acacia (3% and 1.5%) showed good 
redispersibility [11]. 
Kathpalia H et al. prepare ready use cefpodoxime proxetil 
suspension. Antibiotics are not chemically stable in water based on 
pharmaceutical suspensions. Anhydrous liquid antibiotic suspension for 
oral administration provides a product having good shelf life and taste 
characteristics relative to conventional liquid formulations. A ready to 
use oil based cefpodoxime proxetil preparation which can be stored at 
room temperature was prepared and evaluate. The formulation showed 
improved redispersibility, good taste masking of the bitter drug and 
allows the product to be stored longer preventing hydrolysis of the drug 
[12]. 
Prandaya PS et al. design and develop oral reconstitutable 
system of cephalexin as dry syrup to be reconstituted with water and 
then given to children. It was also aimed at determining the influence of 
different processing conditions like powder mixture, granulation and 
compilation product on the properties of the drug product. All the 
formulations showed good organoleptic properties with enhanced 
sedimentation and rheological behavior with t90% within two hours. The 
powder mixture gave a rapid release of 10-30 minutes [13]. 
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Vinod et al formulate taste masked cefuroxime axetil dry 
suspension. The bitter tastes of cefuroxime axetil greatly hamper the 
further development of suitable formulations of this drug for oral use and 
it is important to mask the bitter taste and also make them better for oral 
use. Lubritab is used as a taste masking agent. The taste masked dry 
suspension was made by compaction process. The prepared suspension 
was evaluated for various parameters like sedimentation volume, degree 
of flocculation, drug content and in-vitro dissolution profile and found to 
be within limits[14].  
Sateesha et al prepare formulation and stability study of 
palatable norfloxacin dry syrup: comparison amongst different 
preparation methods. Hence an attempt is finished to develop norfloxacin 
dry syrup. Methods working for formulation are: (i) preparation of 
norfloxacin granules by coating with different levels of acrycoat E100-40 
and (ii) preparation of norfloxacin microspheres using Eudragit E100 and 
subsequent adsorption on different carrier such as lactose, MCC and 
mannitol. The microspheres were smoother and more regular in their 
shape compared to the granules [15]. 
Wiliamson et al prepare improving suspendibility of a water-
insoluble active in a reconstitutable powder for oral suspension. The 
suspendibility of a water-insoluble drug are improved on a sorbitol based 
reconstitutable powder for oral suspension using two novel excipient 
sentry™, polyox™ WSR N80, NF (polyethylene oxide) and avicel CL-
611®NF (MCC /CMC sodium) [16].  
 
7. Patents on Reconstitutable suspension  
Van LA and his collaborator (1994) formulate aqueous 
pharmaceutical suspension with process intended for preparation 
thereof. The present invention relate toward an aqueous pharmaceutical 
suspension contain suspended acetaminophen and at least one added 
pharmaceutical active, a suspension method contain xanthan gum, a 
combination of MCC and sodium CMC and an ancillary suspending agent 
chosen from the group consisting of hydroxyethyl cellulose and a 
pharmaceutically suitable salt of CMC, an useful quantity of a taste-
masking composition; and water, as well as a procedure for producing 
such aqueous pharmaceutical suspensions [17]. 
Romanperez S and his coworker (1996) developed an aqueous 
or T-butanol solvent methods, superficial reconstitute, and submicron-
reconstitute preliposone-lyophilate and process of its preparation and 
use. In one byword, a modified technique designed for the preparation of 
a submicron and firm liposome formulation of the non cross-resistant 
anthracyclineannamycin is preferred[18]. 
Mannalalram GB and his coworker (2005) developed the 
present inventions discloses a novel drug delivery system for proton 
pump inhibitors comprising benzimidazole compounds or their salts, 
preferably rabeprazole or its salts and pharmaceutically suitable 
excipients in powder form which is reconstitutable in a parenterally 
adequate solvent to form an inject able solution[19]. 
Gerold LM and his coworker (2007) developed the present 
creation provide aqueous oral formulations contain sertraline or a 
pharmaceutically suitable salt thereof in addition to sulfoalkyl ether 
cyclodextrine. The liquid formulation can be administered directly or 
diluted before administration[20]. 
Guimberteau and his coworker (2007) prepare the anti-misuse 
micro-particulate oral pharmaceutical dosage form. The invention relate 
to a solid oral pharmaceutical form which is characterize into that it 
contain anti-misuse means, in that at least part of the active principle it 
comprise is limited in coated microparticles for modified release of the 
active principle, and in that the coated microparticles include a coating 
layer which assure modified release of the active principle and 
simultaneously impart crushing resistance to the coated microparticles 
so as to avoid abuse[21]. 
Santiago DC and his collaborator (2008) developed an 
immunosuppressive macrolide powder designed for oral suspension. The 
present invention describe pharmaceutical compassions so as to 
comprise a Tacrolimus powder designed for oral suspension that exhibits 
immense stability as a powder for suspension and also, formerly 
prepared as the extemporaneous suspension, lacking the formation of 
cake similar to clusters, same having a acceptable flavor and a satisfying 
smell. The invention also describes the method for preparing the 
pharmaceutical compositions, same creature a dry process that contain 
mixing Tacrolimus and pre-sieved pharmaceutically suitable carriers for 
a appropriate length of time and the use of the pharmaceutical 
compositions for treat and prevent rejection of transplanted organs and 
atopic dermatitis[22]. 
Frans W and his coworker (2008) formulate the heat stable 
flavouring compositions, One aspect of the present invention relates to 
particulate flavouring compositions having, based on the total weight of 
the composition, 0.1-40 wt % of flavouring substances, 10-90 wt % of one 
or more hydrocolloids, and 0.1-50 wt % of a lipid material having a 
melting point above 75° C. These flavouring compositions are mainly 
suitable for application in food products (including beverages), the 
preparation of which involves one or more heat processing steps, as well 
as in confectionery products such as chewing gum. Other aspects of the 
invention relate to a method of producing a particulate flavouring work of 
art, to a food product containing such a flavouring composition and to a 
process of developed a reconstitutable food product [23]. 
Mitsuho S and his coworker(2008) develop the solid milk and 
method for manufacturing thereof. The object of the present invention is 
to provide solid milk having suitable solubility and strength and a method 
for manufacturing such solid milk. The present invention is based on the 
knowledge that solid milk combining sufficient strength with sufficient 
solubility can be obtained basically by compacting and molding only 
powdered milk as an ingredient under a condition where porosity and 
free fat content thereof are controlled within fixed ranges and then 
humidifying and drying. The above-described object can be attained with 
solid milk with a porosity of 30% to 50% and a method for manufacturing 
solid milk, comprising a compacting process for compacting powdered 
milk and obtaining a solid compacted body of powdered milk, a 
humidifying process for wetting the compacted body of powdered milk 
obtained in the compacting process, and a drying process for drying the 
compacted body of powdered milk humidified in the humidification 
process [24]. 
Jeffrey B his coworker(2008) formulate the Pharmaceutical 
Composition, A novel pharmaceutical composition comprising the NK3 
receptor antagonist talnetant, povidone, mannitol and a surfactant, and a 
process for its preparation are disclosed[25]. 
Matthias R his coworker(2008) formulate the sterile 
suspensions of slightly soluble basic peptide complexes and 
pharmaceutical formulations containing them, the invention provides 
sterile suspensions and sterile lyophilizates of slightly soluble basic 
peptide complexes, and pharmaceutical formulations comprising them. 
The provided sterile suspensions, sterile lyophilizates and 
pharmaceutical formulations comprising them are particularly suitable 
for use in a parenteral dosage form as medicaments for the treatment and 
prophylaxis of diseases and pathological states in mammals, especially in 
humans[26]. 
Travis M and his coworker(2008) prepare the prodrugs of 
phentermine. The invention relates to compositions of amino acid and 
peptide conjugates comprising phentermine. Phentermine is covalently 
attached to at least one amino acid via its amine group to the N-terminus, 
the C-terminus, and a side chain of the peptide carrier. Also discussed are 
methods for treating obesity[27]. 
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Stephane G his coworker (2009)formulate the gas-filled micro-
vesicles with polymer-modified lipids, Image enhancing contrast agents 
for use in diagnostic and/or therapeutic methods, particularly in the form 
of gas-filled micro-vesicles, with enhanced stability. The gas-filled micro-
vesicles are stabilized by a layer of amphiphilic material and comprise 
from 0.15% to 1.0% by moles of a lipid bearing a hydrophilic polymer. 
The lipid bearing a hydrophilic polymer is preferably a phospholipid 
linked to polyethyleneglycol [28]. 
Stephen HW and his collaborator (2009) prepare the use of 
magnesium stearate dihydrate for lubrication of solid pharmaceutical 
compositions. The lubricant compositions may be used to lubricate a 
variety of bioactive formulations including pharmaceutical compositions 
[29]. 
Randal JK and his coworker(2010) prepare the Selective 
targeting of intra-tumoral cells, the present creation relates to the field of 
tumor growth and biology synergistic effects of combined administration 
of mirtazapine and a stimulant compound, the discovery discloses 
combination therapies and formulations of a stimulant (e.g., 
amphetamine) and mirtazapine and their methods of use [30]. 
Rajeev G his co-worker (2010) formulates the stable nano-
particulate drug suspension. A liquid pharmaceutical composition 
comprise an aqueous medium having suspended therein a solid 
particulate Bc1-2 relatives protein inhibitory compound for example 
ABT-263, having a D90 particle size not greater than about 3μm; wherein 
the aqueous medium further comprises at least one pharmaceutically 
acceptable surfactant and at least one pharmaceutically acceptable 
basifying agent such as sodium bicarbonate in amounts that are effective 
together to inhibit particle size increase. The composition is suitable for 
oral or parenteral administration to a subject in need thereof for 
treatment of a disease characterized by over expression of one or more 
anti-apoptotic Bc1-2 family proteins, for example cancer [31]. 
Brian A Salvatore and his coworker (2010) formulate the 
liposomal formulations of tocopheryl amides. Formulate N-chroman 
dicarboxylic acid derivatives and their bioisosteres in liposomal systems. 
Lyophilized liposomal dosage forms of N-chromans, are found to be 
stable, to achieve therapeutically meaningful plasma levels on 
administration to a mammalian host, and to demonstrate selective pro-
apoptotic oncolytic properties in vivo. Advantageously, these 
formulations overcome the systemic toxicity that characterized their 
administration by other dosage forms [32]. 
Jerry TT his collaborator (2010) formulates the formulations 
for treating human and animal diseases. The present disclosure provides 
for a scientific formulation helpful in the management and anticipation of 
human and animal disease. A biologically effective amount of each of the 
components of the formulation is administered to patients in pill (or 
capsule) form via multiple different and identifiable pills. The compounds 
of the formulation are segregated into different pill types, and contain 
various amounts of the compounds curcumin, genistein, squalamine, 
vitamin E, N-acetyl-cysteine, methyl selenocysteine, zinc gluconate, B 
complex, lentinen, Coenzyme Q10 Acetyl-L-carnitine, Lipoic acid, 
resveratrol, and vitamin C. Furthermore, Arabinoxylan and/or Peperine 
might be added to the various pill formulations [33]. 
Travis CM and his coworker (2010) prepare the polar 
hydrophilic prodrugs of amphetamine and additional stimulants and 
processes designed for making and using the same. Disclosed are polar, 
hydrophilic stimulant prodrug compositions comprising at least one 
stimulant chemically attached to a polar hydrophilic ligand, a salt thereof, 
a derivative thereof, or a combination thereof [34]. 
Vincent A his coworker (2010) formulates the sulfoalkyl ether 
cyclodextrin compositions, SAE-CD compositions are provided, along 
with methods of making and using the same. The SAE-CD compositions 
comprise a sulfoalkyl ether cyclodextrin having absorption of less than 
0.5 A.U. due to a drug-degrading agent[35]. 
Catherin C and his coworker (2011) developed the inventions 
relates to the pharmaceutical formulations for oral administration with 
the modified release of active principle, excluding amoxicillin, said 
formulation consisting of suspensions of a coated particles of active 
principle. According to the invention, the microcapsule constituting the 
disperse phase of the suspension are designed to allow the modified 
release of active principle, according to a profile that does not change 
during the storage of the liquid suspension to do this the inventors 
propose the selection of a specific coating composition for the 
microcapsule which consist at least four components that allow these 
microcapsules to be stored in water without modifying their properties of 
modified release of the active principle, this liquid phase furthermore 
being saturated with active principle[36]. 
James DP his coworker (2011) formulates the inhalant 
formulation containing sulfoalkyl ether cyclodextrin and corticosteroid 
prepared beginning a unit dose suspension, an inhalable unit dose liquid 
formulation containing SAE-CD and corticosteroid is provided. The 
formulation is adapted for administration to a subject by nebulization 
with any known nebulizer. SAE-CD present in the formulation 
significantly enhances the chemical stability of corticosteroid, such as 
budesonide. The formulation can also be administered by conventional 
nasal delivery apparatus. The formulation is prepared by mixing SAE-CD, 
in solid or liquid (dissolved) form, with an inhalable suspension-based 
unit dose formulation [37]. 
Hans B his coworker (2011) formulates the pH-dependent 
controlled release pharmaceutical composition designed for non-opioids 
as a result of resistance by the influence of ethanol. The creation relates 
to a pH-dependent controlled release pharmaceutical composition, 
comprise on least one pharmaceutical active ingredient, with the 
exception of opioids, wherein the core is coated at least by one coating 
layer, controlling the release of the pharmaceutical composition, wherein 
the coating layer comprises a polymer mixture of (i) 40-95% by weight, 
based on dry weight of the polymer mixture, of at least one water 
insoluble essentially neutral vinyl polymer or copolymer, and (ii) 5-60% 
by weight, based on dry weight of the polymer mixture, of at least one 
anionic polymer or copolymer, which is insoluble in a buffered medium 
below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, 
characterized in that the coating layer further comprises 110 to 250% by 
weight of a non-porous inert lubricant, 1 to 35% by weight of at least one 
neutral cellulosic compound and 1 to 25% by weight of at least one 
emulsifier, each calculated on dry weight of the polymer mixture [38]. 
Ravis M his coworker (2011) prepare the antidepressant 
prodrugs, the creation provides antidepressant prodrugs comprising an 
antidepressant conjugated to one or more amino acids. The creation also 
relates to pharmaceutical compositions comprising an antidepressant 
prodrug, and toward methods of preparing and using the same [39]. 
Kiavash M his collaborator (2011) prepares the discerning 
targeting of intra-tumoral cells, the present creation relates to the field of 
tumor enlargement and biology. The creation relates to behavior and 
characters of tumor-associated macrophages, and uses of such designed 
for the diagnosis and treatment of cancer and tumor growth [40]. 
John M and his co-worker (2012) developed a controlled 
release oral pharmaceutical dosage forms comprising MGBG. Disclosed 
herein do controlled release oral pharmaceutical dosage forms comprise 
MGBG, in addition toward their use for the enhanced management of 
illness with reduced side effects and longer time on greatest concentrate 
of them [41]. 
Ketan M and his co-worker (2012) developed an orally 
effective methylphenidate extended release powder and aqueous 
suspension product.  An oral methylphenidate powder which is 
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reconstitutable into a final oral aqueous sustained release formulation 
containing at least about 50% or at least about 80% by weight water 
based on the total weight of the suspension is provided. The powder is a 
blend containing a combination of an uncoated methylphenidate –ion 
exchange resin complex, a barrier coated methylphenidate –ion exchange 
resin complex-matrix and a water soluble buffering agent such that upon 
formed into an aqueous liquid formulation. Following administration of a 
single dose of the oral aqueous methylphenidate suspension, a 
therapeutically effective amount of methylphenidate is reached in less 
than one hour and the composition provides a twelve-hour extended 
release profile [42]. 
Ulrich J and his collaborator (2012) the discovery relate 
toward tapentadol (i) used for the treatment of pain in a subject suffering 
from depression and or from anxiety and or (ii) used for the treatment or 
the prevention of depression and or of anxiety [43]. 
Ketan M and his coworker (2012) formulate the abuse resistant opioid 
drug-ion exchange resin complexes having hybrid coatings. A continuous 
release formulation used for opioid drugs is described. The formulations 
contain an opioid-ion exchange resin complex have a hybrid coating. The 
hybrid coatings contain a cured polyvinylacetate polymer and a pH-
dependent enteric coating layer assorted therein. Also provided are 
methods of production and using same [44]. 
Sarjit J his colleague (2012) formulates the method for drying 
biomaterials. The present invention provides a means to concentrate, dry 
and formulate biomaterials such as polysaccharides, gums and linked 
biopolymers, and microorganisms such as cells, spores, and the like from 
dilute solutions using spent germ and added oil bearing residues. In 
adding, the exhausted germ can serve up as a carrier for such 
biomaterials. The sorbed materials are useful in animal feeds [45]. 
Joseph AR and his coworker (2012) formulate the careful 
targeting of intra-tumoral cells, the present invention relates to the 
meadow of tumor growth and biology methods of treating cancer, 
Described are methods and compositions designed for treating epithelial 
tumors through a folate-vinca conjugate in combination with at least one 
other chemotherapeutic agent in which the tumors include ovarian, 
endometrial or non-small cell lung cancer tumors, as well as platinum-
resistant ovarian tumors and platinum-sensitive ovarian tumors [46]. 
Daniela S his coworker (2012) formulates the method for treating chronic 
pain; the present invention provides analgesic compounds comprise on 
least one customized metalloporphyrin compound. Furthermore provide 
are methods to treat pain in orally administer an analgesic compounds 
comprising at least one modified metalloporphyrin compound [47]. 
John MF and his collaborator (2012) prepare the whole seed 
processing and controlled viscosity crop, a method provide a pulverized 
entire seed product from a whole seed have at least 0.01% by total weight 
of oil therein. The whole seed is added to an aqueous carrier which 
physically milled at a shear rate of at least 3000 RPM. The shearing is 
continued until at least 50% by weight of seed solids will pass through a 
square mesh screen having 1.2 mm screen whole dimensions. The solids 
in aqueous carrier are collected as a suspension or dispersion in the 
aqueous carrier. The collected seed solids in aqueous carrier are dried to 
form a free-flowing powder. The free-flowing powder is rehydrated with 
a second aqueous medium to form a non-mucilaginous suspension or 
dispersion [48]. 
Leona GF his partner (2012) prepare the cosmetic sampler 
sheet, a cosmetic sample sheet is provided which includes cosmetics 
enclosed inside or under a solid, water-soluble polymeric film, and 
supported by a substrate sheet. The cosmetics are easily reconstitutable 
by a consumer to permit the consumer to seek different shades or colors 
of particular cosmetics [49]. 
Paul RR his coworker (2012) formulate the nutritionally 
enhanced part from rice bran and process of lowering insulin resistance 
using same, nutritionally enhanced nutraceutical hydrophilic and 
lipophilic rice bran fractions as of rice bran are provided, as well as a 
method of using the same to reduce insulin resistance in animals, 
especially humans with pre-diabetes and type-2 diabetes or others with 
symptoms of metabolic syndrome. Steps are provided with evaluating 
insulin resistance parameters, initiating therapy as well as providing 
therapeutic amounts of hydrophilic and lipophilic rice bran fractions 
from rice bran to treat pre-diabetes and type-2 diabetes or others with 
symptoms of metabolic syndrome, managing compliance with the 
therapy, and monitoring and reevaluating the therapy [50]. 
Walker AL and his associate (2012) formulate the injectable 
meclizine formulations and methods. Methods of treating a vertigo, 
nausea, or vomiting condition comprising injecting a subject with a 
pharmaceutically suitable formulation consisting fundamentally of an 
effectual amount of meclizine or a pharmaceutically acceptable salt 
thereof, a chemically adapted cyclodextrin, and an aqueous carrier 
medium having a pH among concerning 2 and about 7 are disclosed [51]. 
Harshal AJ and his associate (2013) developed a stable, taste 
masked, ready to use suspension comprising rifaximin dispersed in a 
suspension base and one or more pharmaceutically acceptable additives. 
Also provide is a procedure for preparing a stable, taste masked, ready to 
employ suspension of rifaximin comprising the steps of mixing, Rifaximin 
with the suspension base and further sizing the particles of rifaximin by 
way of milling the suspension to get homogenously dispersed rifaximin 
suspension [52]. 
Balasingam RK and his colleague (2013) developed 
pharmaceutical compositions and uses thereof the invention features 
pharmaceutical composition including (i) a drug (ii) a PEG fatty acid ester 
or PPG fatty acid ester in an amount satisfactory to increase the oral 
bioavailability of the drug [53]. 
Alexander VK his collaborator (2013) formulates the water 
soluble fullerene formulations and way of use thereof.  The present 
inventions provide water soluble fullerene formulations and methods of 
use thereof [54]. 
Ramon P and his helper (2013) formulate the make use of 
pten-long head sequence for transmembrane deliverance of molecules. A 
composition for delivering cargo molecules across biological membranes 
is provided comprising (i) a peptide comprise following amino acid 
residue have the series put onward in “SEQ ID NO 1” for the move of a 
cargo molecule across a biological membrane and (ii) the cargo molecule, 
wherein the cargo molecule is not a peptide comprising amino acid 
residue have the series set onward in “SEQ ID NO 4”. Methods of 
delivering cargo molecules across biological membranes are also 
provided. Methods of treating a tumor, cancer, a metabolic disorder, and 
a cardiovascular disorder are also provided [55]. 
Arman S and his coworker (2013) formulate the method and 
composition to improve mechanical resistance of teeth, provide are 
composition and method for preventing dental caries, as well as aqueous 
composition and method for improving the mechanical strength of 
teeth[56]. 
Chi TH and his coworker (2014) prepare the “Hydroxylated 
Polymethoxy Flavone” compositions, provide herein are composition 
enriched in “Polyhydroyxlated Polymethoxy Flavones” valuable as dietary 
supplement, food additives, pharmaceutical and nutraceutical and 
cosmetic composition[57]. 
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Table 2: Patent on reconstitutable suspension 
 
Description Inventors Patent Number Year Ref. 
Aqueous pharmaceutical suspension and process for preparation thereof Van LA et al. 0620001 A1 1994 [17] 
Submicron  liposome suspension obtained from predispose lyophilizates Roman P et al WO1996039121 A1 1996 [18] 
Rabeprazole containing formulation Bajaj MR et al. WO2005065682 A2 2005 [19] 
Taste-masked formulations containing sertaline and sulfoalkyl ether cyclodextrin Gerold  LM et al. EP1742535 A2 2007 [20] 
Anti-misuse microparticulate oral pharmaceutical form Guimberteaueet al. US20070224129 A1 2007 [21] 
Solid milk and method for manufacturing thereof Mitsuho S et al. JP20080292770 2008 [22] 
Immunosuppressive macrolide powder for oral suspension Santiago DC et al. EP2248522 A1 2010 [23] 
Heat stable flavouring compositions Frans W et al. NL20080305239 2008 [24] 
Sterile suspensions of slightly soluble basic peptide complexes and pharmaceutical 
formulations containing them 
Matthias R et al. DE20080255054 2008 [25] 
Prodrugs of phentermine Travis M et al. US20080234206 2008 [26] 
Pharmaceutical composition Jeffrey B et al. US20080255193 2008 [27] 
Gas-filled microvesicles with polymer-modified lipids Stephane G et al. CH20090263330 2009 [28] 
Synergistic effects of combined administration of mirtazapine and a stimulant 
compound 
Randal JK et al. US20090239783 2009 [29] 
Use of magnesium stearate dihydrate for lubrication of solid pharmaceutical 
compositions 
Stephen HW et al. US20090232896 2009 [30] 
Stable nanoparticulate drug suspension Rajeev G et al US20100323020 2010 [31] 
Liposomal formulations of tocopheryl amides Brian AS et al US20100260830 2010 [32] 
Formulations for treating human and animal diseases  Jerry TT et al. US20100209497 2010 [33] 
Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for 
making and using the same 
Travis CM et al. US20100292337 2010 [34] 
Sulfoalkyl ether cyclodextrin compositions Vincent A et al. US20100093663  2010 [35] 
Oral pharmaceutical formulation in the form of aqueous suspension  for modified 
release of active principle 
Catherin C et al. US20110117205 A1 2011 
 
[36] 
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid 
prepared from a unit dose suspension 
James DP et al. US20110008325 2011 [37] 
Antidepressant prodrugs Travis M et al. US20110136742 2011 [38] 
pH dependent controlled release pharmaceutical composition for non-opioids with 
resistance against the influence of ethanol 
Hans Baret al. DE20110229562 2011  
 
[39] 
Selective targeting of intratumoral cells Kiavash M et al.  BE20110262348 2011 [40] 
Controlled release oral pharmaceutical dosage forms comprising mgbg John M et al. US2012/0269891 A1 2012 [41] 
Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings Ketan M et al. US20120148672 2012 [42] 
Method for drying biomaterials Sarjit J et al. US20120088012 2012 [43] 
Method for treating chronic pain Daniela S et al. US20120135973 2012 [44] 
Orally effective methylphenidate extended release powder and aqueous suspension 
product 
Mehta K et al. US2012/0207824 A1 2012 [45] 
Tapentadol for preventing and treating depression and anxiety Ulrich J et al. WO2012146383 A1 2012 [46] 
Nutritionally enhanced fraction from rice bran and method of lowering insulin 
resistance using same 
Paul RR et al. US20120251621 2012 [47] 
Methods of treating cancer Joseph AR et al. US20120122893 2012 [48] 
Injectable meclizine formulations and methods Walker AL et al. US20120108608 2012 [49] 
Cosmetic sampler sheet Leona GF et al. US 20120164194 2012 [50] 
Whole seed processing and controlled viscosity products John MF et al.  US 20120015093 2012 [51] 
Rifamycin ready to use suspension Jahagirdar HA et al. EP2544660 A2 2013 [52] 
Pharmaceutical compositions and uses thereof Balasingam R et al. WO2013059664 A1 2013 [53] 
Water soluble fullerene formulations and methods of use thereof Alexander VK et al. US20130323188 2013  [54] 
Use of pten-long leader sequence for transmembrane delivery of molecules Ramon P et al. US20130171235 2013 [55] 
Methods and compositions to improve mechanical resistance of teeth Arman S et al. US20130129641 2013 [56] 
Hydroxylated polymethoxy flavone compositions Chi-Tang H et al. US20140039044 2014 [57] 
US: United States Patent; WO: World Intellectual Property Organization (WIPO) Patent; EP: Europian Patent; JP: Japan Patent; IN: India Patent; DE: 
Germany Patent; BE: Patent; CH: Patent; NL: Patent 
 
8. Characterization of Suspension [3, 5] 
8.1 SEM analysis 
Scanning electron microscopy (Joel JSM -840A, Japan) / (JSM-
5410LV, Joel, Tokyo, Japan) was used to examine the shape and surface 
morphology of the ethyl cellulose microcapsules. Samples of 
microcapsules were dusted onto double–sided tape on an aluminum stub. 
The stubs were then coated with gold using a cold sputter coater to a 
thickness of 400 0A. The samples were imaged using a 25KV electron 
beam. 
 
8.2 Microscopy studies  
The microscopic observation of suspended microspheres was 
determined using an optical microscope. 
8.3 Repose angle 
For measuring a repose angle of suspension powder, it was 
passed through a conical flask which had a 0.9 cm diameter and was 
laced 10 cm above the horizontal surface. The height (h) of the heap 
formed was measured with a cathetometer and the radius (r) of the cone 
base was also determined. Angle of repose (Φ) was calculated from 
following equation:   Φ=tan-1(h/r)  
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8.4 Rheology 
The Rheology of the suspension was characterized using a 
Brookfield viscometer (meter RM180) with measuring bob no.2 and 
measuring tube no.2. 
8.5 Sedimentation volume:  
The sedimentation volume (F) was obtained based on the 
following equation: f= v1/v0, in which, v1 is the equilibrium volume of 
sediment and v0 is the total volume of suspension. For equilibrium 
volume of sediment the sediment volume which remains unchanged for 3 
weeks was considered. 
8.6 Degree of flocculation  
Degree of flocculation (β) was estimated by the following 
equation: β=f/fα, in which, f is the sedimentation volume of the 
flocculated suspension and fα is the sedimentation volume of the 
suspension when deflocculated. 
8.7 Ease of redispersibility  
For determination of ease of redispersibility (N), the number 
of shears required for redispersibility of a cylindrical glass graduate 
containing dispersed suspension, was considered. 
8.8 Freeze/thaw cycles 
Inspection of physical and microscopic changes of suspension 
undergoing sudden thermal changes was conducted. During this test 
suspensions were kept in a 400C oven for 24 h and then transferred to a 
00C freezer for 24 h. 
8.9 Normal temperature fluctuation  
Inspection of physical and microscopic changes of the 
suspension which occurred during a gradual decrease in temperature 
from 400 C to -50C was also performed. For this purpose, suspensions 
were kept 24 h in each temperature. 
9.10 pH of suspensions 
pH of suspensions was determined using a rot ring pH meter. 
9.11 Drug release studies:  
Drug release studies by using the USP paddle method according to the 
official method and condition. 
8.12 Kinetic models:  
The goodness of fit of release data was tested with the 
mathematical models as the following:  
First-order kinetic: LnW=LnW-k1t,  
Hixon-crowell’s cube root of time: W1/3=W01/3-K2t, 
Squire-root of time: W=W0-kt ½, 
Where W is the amount of drug remaining to be released and W0 is 
the initial amount of drug. 
8.13 Statistical analysis 
Each formulation was prepared in duplicate, and each analysis 
was duplicated. Statistical analysis of the data was performed using 
analysis of variance (single factor) with the aid of Microsoft Excel. 
Differences were considered significant when P  0.05. 
8.14 Stability studies  
The accelerated stability study was done in order to determine 
the expiration date of formulation by placing formulation or samples in 
oven at 400C, 500C and 600C for 90 days. Samples (dry physical mixture 
powder or granules) were taken and assayed for their drug content at a 
suitable time intervals using UV spectrophoto-metrical method for the 
accepted formulation and also, physical stability (color, odor and pH) 
changes for the samples were examined.  
 
9. Marketed formulation of controlled release suspension 
 
Table1: Marketed Formulations of controlled release suspension 
 
Sr. No. Brand Name Generic Name Company 
1 Zmax SR Azithromycin Di-hydrate Pfizer 
2 Delsym Dextromethorphan HBr Reckit Benckiser 
3 Paxil Paroxitin HCL Gsk 
4 Nexium Esomeprazole Astra Zeneca 
5 Micro-k Potassium chloride THER- Rx Corp. 
6 Tussionex Hydrocodone and chlorpheniramine Ucb 
7 Dynahist-er Chlorampheniramine and Pseudoephedrine Wolters Kluwer Heatlh 
8 AugmentinR Syrup Amoxycillin and Potasium clavunate GlaxoSmithKline 
 
10. Conclusion 
Reconstitutable SR suspension is a method to increase the 
duration of drug action being formulated without affecting onset of 
action. SR suspension affected by coating the drug to be formulated as 
suspension by insoluble polymer coating. The polymer coating provides 
sustained release action and also masks the taste of the bitter drug. 
Among the oral reconstitutable controlled release suspensions are 
becoming more popular. Because they pass through the gut as if a 
solution, avoiding the vagaries of gastric emptying and different transit 
rates, spread over a large area of absorbing mucosa, preventing exposure 
to high drug concentrations, maximum absorption, minimize side effect, 
applicable to two or more active ingredients, release drug in a more 
predictable manner. The main advantage of SR suspension is decrease in 
dosing frequency. Commencing this review piece of writing it can be 
accomplished to the most important necessity of a successful SR 
invention focuses lying on augment patient compliance and attends 
preferred curative concentration into the least amount dosage frequency. 
This can be achieving by formulate the reconstitutable SR suspension. 
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